aBLA Filing Intelligence & Biosimilar Opportunity

Penpulimab-Kcqx

Anticancer

Intravenous Injection

Penpulimab‑Kcqx is an intravenous PD‑1 inhibitor used with chemotherapy to treat recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. It boosts immune response to help control tumor growth in patients who have progressed after prior therapies.

Approval Date

23-Apr-25

Data Exclusivity Expiry

23-Apr-29

Market Exclusivity Expiry

23-Apr-37

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

101

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Penpulimab-Kcqx

Innovator

AKESO BIOPHARMA CO., LTD

Dosage Form

Intravenous Injection

Strength

100 mg/10 mL (10 mg/mL)

Therapeutic Category

Anticancer

Usage

In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Penpulimab-Kcqx

Market performance & projections

Details & specifications

Frequently asked questions

Ready to act on this opportunity?

Why Spring Bio Solution

Login With

Are you sure want to logout from NCE Grid?